Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma

PURPOSE: Ipilimumab (IPI), a monoclonal antibody against immune-checkpoint receptor cytotoxic T lymphocyte antigen-4, is designed to enhance antitumor T cell function. IPI 10 mg/kg plus dacarbazine (DTIC) significantly improved overall survival in a phase 3 study involving predominantly Caucasian pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, N., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Kiyohara, Y., Tsutsumida, A., Namikawa, K., Okuyama, R., Otsuka, Y., Tokudome, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612320/
https://www.ncbi.nlm.nih.gov/pubmed/26407818
http://dx.doi.org/10.1007/s00280-015-2870-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612320/
https://www.ncbi.nlm.nih.gov/pubmed/26407818
http://dx.doi.org/10.1007/s00280-015-2870-0

Ejemplares similares